Gyre Therapeutics, Inc.
GYRE
Revenue
25.23M
▼-1.95M▼-7.17%
3 Months ChangeAssets
120.93M
▼-1.08M▼-0.8860%
3 Months ChangeLiabilities
27.58M
▼-5.66M▼-17.02%
3 Months ChangeFree Cash Flow
2.65M
▼-6.02M▼-69.42%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-08-13
Form 10-Q
ID: 0000950170-24-096159
2024-08-13
Form 8-K
ID: 0000950170-24-095687
2024-08-08
Form 8-K
ID: 0001140361-24-036404
2024-07-05
Form 8-K
ID: 0001140361-24-032511
2024-06-17
Form 8-K
ID: 0001140361-24-030348
2024-05-30
Form 8-K
ID: 0001140361-24-028106
2024-05-13
Form 10-Q
ID: 0000950170-24-058642
2024-05-09
Form 8-K
ID: 0000950170-24-056893
2024-05-08
Form 8-K
ID: 0001140361-24-024799
2024-03-26
Form 8-K
ID: 0001140361-24-015318